EA200901630A1 - Способы введения доз для лечения аутоиммунных заболеваний при использовании taci-ig слитого белка, такого как атацицепт - Google Patents

Способы введения доз для лечения аутоиммунных заболеваний при использовании taci-ig слитого белка, такого как атацицепт

Info

Publication number
EA200901630A1
EA200901630A1 EA200901630A EA200901630A EA200901630A1 EA 200901630 A1 EA200901630 A1 EA 200901630A1 EA 200901630 A EA200901630 A EA 200901630A EA 200901630 A EA200901630 A EA 200901630A EA 200901630 A1 EA200901630 A1 EA 200901630A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
taci
administration
ataccept
autoimmune diseases
Prior art date
Application number
EA200901630A
Other languages
English (en)
Other versions
EA022911B1 (ru
Inventor
Шарон Дж. Басби
Джейн А. Гросс
Дженифер Визич
Иван Несторов
Ален Мунафо
Орестис Папасоулиотис
Клаудиа Пена-Росси
Original Assignee
Займодженетикс, Инк.
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Займодженетикс, Инк., Арес Трейдинг С.А. filed Critical Займодженетикс, Инк.
Publication of EA200901630A1 publication Critical patent/EA200901630A1/ru
Publication of EA022911B1 publication Critical patent/EA022911B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В различных воплощениях настоящее изобретение обеспечивает способы, композиции, дозировки и режимы введения для лечения аутоиммунных заболеваний, включая системную эритематозную волчанку (SLE), например включающие введение пациенту, который нуждается в таком лечении, TACI-Ig слитой молекулы, такой как атацицепт. В одном воплощении TACI-Ig слитая молекула вводится в количестве, достаточном для замедления, ослабления или ингибирования функций индукции пролиферации BLyS и APRIL, в частности используются многократное введение слитой молекулы при относительно низкой дозе в течение курса лечения.
EA200901630A 2007-06-13 2008-06-13 Способ лечения пациента, страдающего i или ii стадией системной красной волчанки EA022911B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94361807P 2007-06-13 2007-06-13
US2403108P 2008-01-28 2008-01-28
PCT/US2008/066945 WO2008157369A2 (en) 2007-06-13 2008-06-13 Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus

Publications (2)

Publication Number Publication Date
EA200901630A1 true EA200901630A1 (ru) 2010-06-30
EA022911B1 EA022911B1 (ru) 2016-03-31

Family

ID=40097164

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901630A EA022911B1 (ru) 2007-06-13 2008-06-13 Способ лечения пациента, страдающего i или ii стадией системной красной волчанки

Country Status (22)

Country Link
US (1) US20090186040A1 (ru)
EP (1) EP2167038B1 (ru)
JP (3) JP2010530000A (ru)
CN (2) CN101790369A (ru)
AU (1) AU2008265974B2 (ru)
CA (1) CA2690119A1 (ru)
CY (1) CY1120830T1 (ru)
DK (1) DK2167038T3 (ru)
EA (1) EA022911B1 (ru)
ES (1) ES2681195T3 (ru)
HR (1) HRP20181184T1 (ru)
HU (1) HUE038445T2 (ru)
IL (1) IL202305B (ru)
LT (1) LT2167038T (ru)
MX (1) MX2009013183A (ru)
PL (1) PL2167038T3 (ru)
PT (1) PT2167038T (ru)
SG (1) SG182191A1 (ru)
SI (1) SI2167038T1 (ru)
TR (1) TR201806960T4 (ru)
WO (1) WO2008157369A2 (ru)
ZA (1) ZA200908274B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169966B (zh) * 2013-04-09 2015-04-01 中国人民解放军军事医学科学院基础医学研究所 一种治疗系统性红斑狼疮的药物组合物
KR20220034742A (ko) * 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
MX2022013998A (es) * 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
IL308336A (en) * 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094879A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
AUPS057102A0 (en) * 2002-02-15 2002-03-07 Vri Biomedical Ltd Compositions and methods for treatment of skin disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
KR20070001880A (ko) * 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
KR20080056714A (ko) * 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
CN101489573B (zh) * 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2009082511A1 (en) * 2007-12-20 2009-07-02 Elc Management Llc Methods and compositions for treating skin

Also Published As

Publication number Publication date
LT2167038T (lt) 2018-05-25
ES2681195T3 (es) 2018-09-12
WO2008157369A3 (en) 2009-02-19
PL2167038T3 (pl) 2018-10-31
CY1120830T1 (el) 2019-12-11
SG182191A1 (en) 2012-07-30
CN101790369A (zh) 2010-07-28
AU2008265974A1 (en) 2008-12-24
PT2167038T (pt) 2018-06-01
CN105770891A (zh) 2016-07-20
JP2015013887A (ja) 2015-01-22
EP2167038B1 (en) 2018-04-25
CA2690119A1 (en) 2008-12-24
MX2009013183A (es) 2010-01-20
ZA200908274B (en) 2012-02-29
EP2167038A2 (en) 2010-03-31
TR201806960T4 (tr) 2018-06-21
HRP20181184T1 (hr) 2018-09-21
US20090186040A1 (en) 2009-07-23
SI2167038T1 (en) 2018-08-31
JP2017031209A (ja) 2017-02-09
WO2008157369A2 (en) 2008-12-24
EA022911B1 (ru) 2016-03-31
HUE038445T2 (hu) 2018-10-29
IL202305B (en) 2018-06-28
JP2010530000A (ja) 2010-09-02
IL202305A0 (en) 2010-06-30
AU2008265974A8 (en) 2010-01-07
DK2167038T3 (en) 2018-08-06
AU2008265974B2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
MX2009000812A (es) Soluciones de metotrexato concentradas.
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
EA201690738A1 (ru) Ингалятор сухого порошка
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
RU2013121788A (ru) Ингибиторы репликации вич
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA200901155A1 (ru) Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии
EA200970224A1 (ru) Лечение заболеваний хряща
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
BR112019005168A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
EA200901630A1 (ru) Способы введения доз для лечения аутоиммунных заболеваний при использовании taci-ig слитого белка, такого как атацицепт
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
MX2009013779A (es) Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r.
EA201590697A1 (ru) Производные кетамина
EA200870535A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ С ИСПОЛЬЗОВАНИЕМ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM